期刊
LEUKEMIA & LYMPHOMA
卷 62, 期 8, 页码 1973-1981出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1889539
关键词
AML; MRD; allogenic stem cell transplantation; overall survival; multiparameter flow cytometry
资金
- Swedish Association of Local Authorities and Regions
- Region Skane
- Regional Cancer Center South
The Swedish national guidelines for AML treatment recommend analyzing MRD using MFC in the clinical setting. Most AML patients in complete remission after intensive chemotherapy had MRD-negative results, but there was no clear association with overall survival. Clinician awareness of the importance of MRD status could improve treatment outcomes.
The Swedish national guidelines for treatment of acute myeloid leukemia (AML) recommend analysis of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in bone marrow in the routine clinical setting. The Swedish AML registry contains such MRD data in AML patients diagnosed 2011-2019. Of 327 patients with AML (non-APL) with MRD-results reported in complete remission after two courses of intensive chemotherapy 229 were MRD-negative (70%), as defined by <0.1% cells with leukemia-associated immunophenotype in the bone marrow. MRD-results were reported to clinicians in real time. Multivariate statistical analysis adjusted for known established risk factors did not indicate an association between MFC-MRD and overall survival (HR: 1.00 [95% CI 0.61, 1.63]) with a median follow-up of 2.7 years. Knowledge of the importance of MRD status by clinicians and individualized decisions could have ameliorated the effects of MRD as an independent prognostic factor of overall survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据